Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

Technology appraisal guidance
Reference number: TA832
Published: 19 October 2022

Register as a stakeholder

Tools and resources

Tools and resources to help you put the guidance into practice.

Implementation support

Webinar: Supporting individualised treatment choices in endometriosis

Education

Linzagolix or relugolix-estradiol-norethisterone for uterine fibroids: a discussion guide for healthcare professionals and patients (PDF 1.04 MB)

Published:

29 April 2026

Resource impact

Resource impact template
Resource impact template (Excel 2.23 MB)

Published:

28 November 2025
Resource impact statement

Guidance into practice